VivoSeq
Oncology

Gallbladder Cancer

29

Pipeline Programs↗

5

Active Trials↗

16

Companies Involved↗

Gallbladder Cancer is an emerging landscape with 29 programs across 16 companies. The most active players are Astex Pharmaceuticals, Inc., Eastern Cooperative Oncology Group, Roche. 3 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

77/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Astex Pharmaceuticals, Inc.

1 program

Phase 1E

Eastern Cooperative Oncology Group

2 programs

Phase 2Roche logo

Roche

2 programs

Phase 2G

Gynecologic Oncology Group

2 programs

Phase 2Teva logo

Teva

1 program

Phase 2T

Tracon Pharmaceuticals Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

22 of 30 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody827%

Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 100% of 30 pipeline programs.

Analysis

Trial Status

19

clinical trials

Completed10 · 53%
Terminated2 · 11%
Not yet recruiting2 · 11%
Withdrawn1 · 5%
Enrolling by invitation1 · 5%
Recruiting1 · 5%
Other2 · 11%

Clinical Trials

Trial Activity

19 trials

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
Recruiting·LLu Wang, MD, PhD·Phase 2·NCT05757336·50 enrolled
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Active, not recruiting·UUniversity of Southern California·Phase 1·NCT03257761·55 enrolled
A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05919095·37 enrolled
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer
Not yet recruiting·FFudan University·Phase 2·NCT06591650·33 enrolled
Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer
Enrolling by invitation·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT07310069·44 enrolled
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer
Completed·MMassachusetts General Hospital·Phase 2·NCT00142480·8 enrolled
Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00009893·42 enrolled
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Completed·National Cancer Institute (NCI)·Phase 2·NCT02042443·53 enrolled
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer
Completed·MMassachusetts General Hospital·Phase 2·NCT00361231·35 enrolled
Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00075504·33 enrolled
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT03201458·86 enrolled
Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
Completed·UUniversity of Rochester·Phase 2·NCT01308840·31 enrolled
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
Completed·UUniversity of Chicago·Phase 2·NCT00003557·16 enrolled
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00033462·78 enrolled
Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
Completed·Alliance for Clinical Trials in Oncology·Phase 1/2·NCT00059865·68 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)